Exogenous opioid peptides derived from food proteins and their possible uses as dietary supplements: A critical review

Food Reviews International

Volumn 34, Issue 1, 2018, Pages 70-86

  Stefanucci, Azzurra ^a   Mollica, Adriano ^a   Macedonio, Giorgia ^a   Zengin, Gokhan ^b   Ahmed, Abdelkareem A ^c   Novellino, Ettore ^d  

^a UNIVERSITY OF CHIETI   (Italy)

^b SELCUK UNIVERSITY   (Turkey)

^c UNIVERSITY OF NYALA   (Sudan)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Casein; casomorphin; exorphins; milk; nutraceuticals; opioid

Indexed keywords

CASEIN; CHEMICAL CONTAMINATION; DIETARY SUPPLEMENTS; PEPTIDES;

CASOMORPHIN; EXORPHINS; MILK; NUTRACEUTICALS; OPIOID;

PROTEINS;

EID: 85032220751     PISSN: 87559129     EISSN: 15256103     Source Type: Journal    
DOI: 10.1080/87559129.2016.1225220     Document Type: Review

References (144)

1. Rautiainen, S.,; Manson, J.E.,; Lichtenstein, A.H.,; Sesso, H.D., Dietary supplements and disease prevention - a global overview. Nat. Rev. Endocrinol. 2016, 12, 407–420.
2. Aronson, J.K., Defining “nutraceuticals”: Neither nutritious nor pharmaceutical. Br. J. Clin. Pharmacol. 2016, in press. doi: 10.1111/bcp.12935.
3. Novellino, E.,; Santini, A., Nutraceuticals: Beyond the diet before the drugs. Curr. Bioact. Compd. 2014, 12, 1–12.
4. Nongonierma, A.D.,; FitzGerad, R.J., Bioactive properties of milk proteins in humans: A review. Peptides. 2015, 73, 20–34.
5. Kitts, D.D.,; Weiler, K., Bioactive proteins and peptides from food sources. Applications of bioprocesses used in isolation and recovery. Curr. Pharm. Des. 2003, 9, 1309–1323.
6. Karelin, A.A.,; Blischenko, E.Y.,; Ivanov, V.T., A novel system of peptidergic regulation. FEBS Lett. 1998, 428, 7–11.
7. Guinane, C.M.,; Cotter, P.D., Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Ther. Adv. Gastroenterol. 2013, 6, 295–308.
8. Reichelt, K.L.,; Tveiten, D.,; Knivsberg, A.,; Brønstad, G., Peptides’ role in autism with emphasis on exorphins. Microb. Ecol. Healt Dis. 2012, 23, 18958.
9. Molina, P.E.,; Abumrad, N.N., Metabolic effects of opiates and opioid peptides. Adv. Neuroimmunol. 1994, 4, 105–116.
10. Diziuba, J.,; Minkiewicz, P.,; Nalecz, D.,; Iwaniak, A., Database of biologically active peptide sequences. Nahrung. 1999, 43, 190–195.
11. Calvo, C.F.,; Cesselin, F.,; Gelman, M.,; Glowinski, J., Identification of an opioid peptide secreted by rat embryonic mixed brain cells as a promoter of macrophage migration. Eur. J. Neurosci. 2000, 12, 2676–2684.
12. Sturner, R.A.,; Chang, K.J., Opioid peptide content in infant formulas. Pediatr. Res. 1988, 23, 4–10.
13. Höllt, V., Opioid peptide processing and receptor selectivity. Ann. Rev. Pharmacol. Toxicol. 1986, 26, 59–77.
14. Giordano, C.,; Sansone, A.,; Masi, A.,; Lucente, G.,; Punzi, P.,; Mollica, A.,; Pinnen, F.,; Feliciani, F.,; Cacciatore, I.,; Davis, P.,; Lai, J.,; Ma, S.-W.,; Porreca, F.,; Hruby, V., Synthesis and activity of endomorphin-2 and morphiceptin analogues with proline surrogates in position 2. Eur. J. Med. Chem. 2010, 45, 4594–4600.
15. Teschemacher, H., Atypical opioid peptides. In Handb. Exp. Pharmacol: Opioids I; Hertz, A., Ed.; Springer Verlag: Berlin, Germany, 1993; pp 499–528.
16. Grobe, N.,; Lamshöft, M.,; Orth, R.G.,; Dräger, B.,; Kutchan, T.M.,; Zenk, M.H.,; Spiteller, M., Urinary excretion of morphine and biosynthetic precursors in mice. PNAS 2010, 107, 8147–8152.
17. Mollica, A.,; Stefanucci, A.,; Costante, R.,; Hruby, V.J., Rational approach to the design of bioactive peptidomimetics: Recent developments in opioid agonist peptides. Studies in Natural Products Chemistry 2015, 46, 27–68.
18. Mollica, A.,; Pinnen, F.,; Costante, R.,; Locatelli, M.,; Stefanucci, A.,; Pieretti, S.,; Davis, P.,; Lai, J.,; Rankin, D.,; Porreca, F.,; Hruby, V.J., Biological active analogues of the opioid peptide biphalin: Mixed α/β3-peptides. J. Med. Chem. 2013, 56, 3419–3423.
19. Mollica, A.,; Pinnen, F.,; Feliciani, F.,; Stefanucci, A.,; Lucente, G.,; Davis, P.,; Porreca, F.,; Ma, S.W.,; Lai, J.,; Hruby, V.J., New potent biphalin analogues containing p-fluoro-L-phenylalanine at the 4,4’ positions and non-hydrazine linkers, Amino acids. 2011, 40, 1503–1511.
20. Mollica, A.,; Davis, P.,; Ma, S.-W.,; Lai; J., Porreca, F.,; Hruby, V.J. Synthesis and biological evaluation of new biphalin analogues with non-hydrazine linkers Bioorg. Med. Chem. Lett. 2005, 15, 2471–2475.
21. Paroli, E., Opioid peptides from food (the exorphins). World Rev. Nutr. Diet 1988, 55, 58–97.
22. Meisel, H.,; Schlimme, E., Milk proteins: precursors of bioactive peptides. Trends Food Sci. Technol. 1990, 1, 41–43.
23. Huebner, F.R.,; Lieberman, K.W.,; Rubino, R.P.,; Wall, J.S., Demonstration of high opioid-like activity in isolated peptides from wheat gluten hydrolysates. Peptides. 1984, 5, 1139–1147.
24. Zioudrou, C.,; Streaty, R.A.,; Klee, W.A., Opioid peptides derived from food proteins. The exorphins. J. Biol. Chem. 1979, 254, 2446–2449.
25. Takahashi, M.,; Moriguchi, S.,; Yoshikawa, M.,; Sasaki, R., Isolation and characterization of oryzatensin: a novel bioactive peptide with ileum-contracting and immunomodulating activities derived from rice albumin. Biochem. Mol. Biol. Int. 1994, 33, 1151–1158.
26. Ohinata, K.,; Agui, S.,; Yoshikawa, M., Soymorphins, novel μ opioid peptides derived from soy β-conglycin β-subunit, have anxiolytic activities. Biosci. Biotechnol. Biochem. 2007, 71, 2618–2621.
27. Nyberg, F.,; Sanderson, K.,; Glamsta, E.L., The hemorphins: a new class of opioid peptides derived from the blood protein hemoglobin. Biopolymers. 1997, 43, 147–156.
28. Zhao, Q.,; Garreau, I.,; Sannier, F.,; Piot, J.M., Opioid peptides derived from hemoglobin: hemorphins. Biopolymers. 1997, 43, 75–98.
29. Yoshikawa, M.,; Tani, F.,; Chiba, H., Peptide Chemistry; Shiba, T., Ed.; Protein Research Foundation: Osaka, 1988; pp 473–476.
30. Henschen, A.,; Lottspeich, F.,; Brantl, V.,; Teschemacher, H., Novel opioid peptides derived from casein (β-casomorphins). II. Structure of active components from bovine casein peptone. Z. Physiol. Chem. 1979, 360, 1217–1224.
31. Umbach, M.,; Teschemacher, H.,; Praetorius, K.,; Hirschhauser, R.,; Bostedt, H., Demonstration of a β-casomorphine immunoreactive material in the plasma of newborn calves after milk intake. Regul. Pept. 1985, 12, 223–230.
32. Graf, M.V.,; Hunter, C.A.,; Kastin, A.J., Presence of delta-sleep-inducing peptide-like material in human milk. J. Clin. Endocrinol. Metab. 1984, 59, 127–132.
33. Nyberg, F.,; Brantl, V., β-Casomorphins and related peptides. Proceedings from the First International Symposium on β-Casomorphins and related peptides. 1990, Fyris-Trynk Ab, Uppsala, Sweden.
34. Schulte-Frohlinde, E.,; Schmid, R.,; Brantl, V.,; Schusdziarra, V., β-Casomorphins and related peptides: Recent developments; VCH: New York, 1994.
35. Mansfeld, R.,; Kauntni, J.,; Grunert, E.,; Brantl, V.,; Jöchle, W., β-Casomorphins and related peptides. In Proceedings from the First International Symposium on β-Casomorphins and related peptides. Fyris-Trynk Ab: Uppsala, Sweden, 1990.
36. Daniel, H.,; Vohwinkel, M.,; Rehner, G., Effect of casein and β-casomorphins on gastrointestinal motility in rats. J. Nutr. 1990, 120, 252–257.
37. Defilippi, C.,; Gomez, E.,; Charlin, V.,; Silva, C., Inhibition of small intestinal motility by casein: a role of beta casomorphins? Nutrition 1995, 11, 751–754.
38. Blass, E.M., Milk-induced hypoalgesia in human newborns. Pediatrics 1997, 99, 825–829.
39. Mihatsch, W.A.,; Högel, J.,; Pohlandt, F., Hydrolysed protein accelerates the gastrointestinal transport of formula in preterm infants. Acta Paediatr. 2001, 90, 196–198.
40. Marcone, S.,; Belton, S.,; Fitzgerald, D.J., Milk-derived bioactive peptides and their health promoting effects: a potential role in atherosclerosis. Br. J., Clin. Pharmacol. 2016, in press. doi: 10.1111/bcp.13002.
41. Wadley, G.,; Martin, A., The origins of agriculture a biological perspective and a new hypothesis. J. Australas. Coll. Nutr. Envir. Med. 2000, 19, 3–12.
42. Meisel, H., Overview on milk protein-derived peptides. Int. dairy J. 1998, 8, 363–373.
43. Meisel, H.,; Bernard, H.,; Fairweather-Tait, S.,; FitzGerald, R.J.,; Hartmann, R.,; Lane, C.N.,; McDonagh, D.,; Teucher, B.,; Wal, J.M., Nutraceutical and functional food ingredients for food and pharmaceutical applications. Br. J. Nutr. 2001, 85, 635–635.
44. Meisel, H., Bioactive peptides from milk proteins: A perspective for consumers and producers. Aust. J. Dairy Technol., 2001, 56, 83–92.
45. Berner, L.A.,; O’Donnell, J.A., Functional foods and health claims legislation: Applications to dairy foods. Int. Dairy J. 1998, 8, 355–362.
46. Tiruppathi, C.,; Miyamoto, Y.,; Ganapathy, V.,; Roesel, R.A.,; Whitford, G.M.,; Leibach, F.H., Hydrolysis and tran sport of proline-containing peptides in renal brush-border membrane vescicles from dipeptidyl peptidase IV-positive and dipeptidyl peptidase IV-negative rat strains. J. Biol. Chem. 1990, 265, 1476–1483.
47. Kreil, G.,; Umbach, M.,; Brantl, V.,; Teschemacher, H., Study on the enzymatic degradation of β-casomorphin. Life Sci. 1993, 33, 137–140.
48. Jinsmaa, Y.,; Yoshikawa, M., Enzymatic release of neocasomorphin and β-casomorphin from bovine β-casein. Peptides. 1999, 20, 957–962.
49. Svedberg, J.,; de Haas, J.,; Leimenstoll, G.,; Paul, F.,; Teschemacher, H., Demonstration of β-casomorphin immunoreactive materials in In vitro digests of bovine milk and in small intestine contests after bovine milk ingestion in adult humans. Peptides 1985, 6, 825–830.
50. Chabance, B.,; Marteau, P.,; Rambaud, J.C.,; Migliore-Samour, D.,; Boynard, M.,; Perrotin, P.,; Guillet, R.,; Jollès, P.,; Fiat, A.M., Casein peptide release and passage to the blood in humans during digestion of milk or yogurt. Biochimie 1998, 80, 155–165.
51. McLachlan, C.N., β-casein A1, ischaemic heart disease mortality, and other illnesses. Med. Hypotheses 2001, 56, 262–272.
52. Elliott, R.B.,; Harris, D.P.,; Hill, J.P.,; Bibby, N.J.,; Wasnuth, H.E., Type I (insulin independent) diabetes mellitus and cow milk: casein variant consumption. Diabetologia 1999, 42, 292–296.
53. Tailford, K.A.,; Berry, C.L.,; Thomas, A.C.,; Campbell, J.H., A casein variant in cow’s milk is atherogenic. Atherosclerosis 2003, 170, 13–19.
54. Sun, Z.,; Zhang, Z.,; Wang, X.,; Cade, R.,; Elmer, Z.,; Fregly, M., Relation of β-casomorphin to apnea in sudden infant death syndrome. Peptides 2003, 24, 937–943.
55. Bell, S.J.,; Grochoski, G.T.,; Clarke, A.J., Health implications of milk containing β-casein with the A2 genetic variant. Crit. Rev. Food Sci. Nutr. 2006, 46, 93–100.
56. Kamiñski, S.,; Cieoeliñska, A.,; Kostyra, E., Polymorphism of bovine beta-casein and its potential effect on human health. J. Appl. Genet. 2007, 8, 189–198.
57. Teschemacher, H.,; Umbach, M.,; Hamel, U.,; Praetorius, K.,; Ahnert-Hilger, G.,; Brantl, V.,; Lottspeich, F.,; Henschen, A., No evidence for the presence of β-casomorphins in human plasma after injections of cows’ milk or milk products. J. Dairy Res. 1986, 53, 135–138.
58. Blass, E.M.,; Blom, J., β-casomorphin causes hypoalgesia in 10-day-old rats: Evidence for central mediation. Pediatr. Res. 1996, 39, 199–203.
59. Ermisch, A.,; Ruhle, J.H.,; Landgraf, R.,; Hess, J., Blood-brain barrier and peptides. J. Cereb. Blood flow Metab. 1985, 5, 350–357.
60. Pasi, A.,; Mahler, H.,; Lansel, N.,; Bernasconi, C.,; Messiha, F.S., β-Casomorphin-immunoreactivity in the brain stem of the human infant. Res. Commun. Chem. Pathol. Pharmacol. 1993, 80, 305–322.
61. Lindstrom, L.H.,; Nyberg, F.,; Terenius, L.,; Bauer, K.,; Besev, G.,; Gunne, L.M.,; Lyrenas, S.,; Lund, G.W.,; Lindberg, B., CSF and plasma β-casomorphin-like opioid peptides in postpartum psychosis. Am. J. Psychiatry. 1984, 141, 1059–1066.
62. Banks, W.A.,; Kastin, A.J., Saturable transport of peptides across the blood-brain barrier. Life Sci. 1987, 41, 1319–1338.
63. Mussell, M.,; Kroenke, K,; Spitzer, R.L.,; Williams, J.B.,; Herzog, W.,; Lowe, B., Gastrointestinal symptoms in primary care: prevalence and association with depression and anxiety. J. Psychosom. Res. 2008, 64, 605–612.
64. Spiller, R.,; Aziz, Q.,; Creed, F.,; Emmanuel, A.,; Houghton, L.,; Hungin, P.,; Jones, R.,; Kumar, D.,; Rubin, G.,; Trudgill, N.,; Whorwell, P., Guidelines on the irritable bowel syndrome: Mechanisms and practical management. Gut 2007, 56, 1770–1798.
65. O’Mahony, S.M.,; Marchesi, J.R.,; Scully, P.,; Codling, C.,; Ceolhom A.M.,; Quigley, E.M.,; Cryan, J.F.,; Dinan, T.G., Early life stress alters behavior, immunity, and microbiota in rats: Implications for irritable bowel syndrome and psychiatric illnesses. Biol. Psychiatry 2009, 65, 263–267.
66. Nakade, Y.,; Fukuda, H.,; Iwa, M.,; Tsukamoto, K.,; Yanagi, H.,; Yamamura, T.,; Mantyh, C.,; Pappas, T.N.,; Takahashi, T., Restraint stress stimulates colonic motility via central corticotropin-releasing factor and peripheral 5-HT3 receptors in conscious rats. Am. J. Physiol. Gastrointest. Liver. Physiol. 2007, 292, G1037–44.
67. Bercik, P.,; Verdu, E.F.,; Foster, J.A.,; Lu, J.,; Scharringa, A,; Kean, I.,; Wang, L.,; Blennerhassett, P., Collins, S.M., Role of gut-brain axis in persistent abnormal feeding behavior in mice following eradication of Helicobacter pylori infection. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296, R587–94.
68. Bravo, J.A.,; Forsythe, P.,; Chew, M.V.,; Escaravage, E.,; Savignac, H.M.,; Dinan, T.M.,; Bienenstock, J.,; Cryan, J.F., Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc. Nat. Acad. Sci. USA 2011, 108, 16050–16055.
69. Mayer, E.A., Gut feelings: The emerging biology of gut-brain communication. Nat. Rev. Neurosci. 2011, 12, 453–466.
70. Furness, J.B., A comprehensive overviewof all aspects of the enteric nervous system. In The Enteric Nervous System. Blackwell: Oxford, 2006.
71. Furness, J.B.,; Kunze, W.A.,; Bertrand, P.P.,; Clerc, N.,; Bornstein, J.C.,; Intrinsic primary afferent neurons of the intestine. Prog. Neurobiol. 1998, 54, 1–18.
72. Costa, M.,; Furness, J.B.,; Llewellyn-Smith, I.J., Physiology of the Gastrointestinal Tract; Johnson, LR.,; Alpers, D.H.; Jacobson, E.D.; Walsh, J.H., Eds.;. Raven Press: New York, 1987; pp 1–40.
73. Gershon, MD.,; Kirchgessner, A.L.; Wade, P.R. Functional anatomy of the enteric nervous system. In Physiology of the gastrointestinal tract; Johnson, L.R.; Alpers, D.H.; Jacobson, E.D.; Walsh, J.H., Eds.; Raven Press: New York, 1994; pp 381–422.
74. Kurokawa, K.,; Itoh, T.,; Kuwahara, T.,; Oshima, K.,; Toh, H.,; Toyoda, A.,; Takami, H.,; Morita, H.,; Sharma, V.K.,; Srivastava, T.P.,; Taylor, T.D.,; Noguchi, H.,; Mori, H.,; Ogura, Y.,; Ehrlich, D.S.,; Itoh, K.,; Takagi, T.,; Sakaki, Y.,; Hayashi, T.,; Hattori, M., Comparative metagenomics revealed commonly enriched gene sets in human gut microbiomes. DNA Res. 2007, 14, 169–181.
75. Tillisch, K.,; Labus, J.,; Kilpatrick, L.,; Jiang, Z,; Stains, J.,; Ebrat, B.,; Guyonnet, D.,; Legrain-Raspaud, S.,; Trotin, B.,; Naliboff, B.,; Mayer, E.A., Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology. 2013, 144, e4.
76. Zollner, C.,; Stein, C., Opioids. Handb. Exp. Pharmacol. 2007, 177, 31–63.
77. Holzer, P., Opioid receptors in the gastrointestinal tract. Regul. Pept. 2009, 155, 11–17.
78. Yeomans, M.R.,; Gray, R.W., Opioid peptides and the control of human ingestive behaviour. Neurosci. Biobehav. Rev. 2002, 26, 713–728.
79. Greenwood-Van Meerveld, B.,; Gardner, C.J.,; Little, P.J.,; Hicks, G.A.,; Dehaven-Hudkins, D.L., Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol. Motil. 2004, 16, 46–53.
80. Reimer, K.,; Hopp, M.,; Zenz, M.,; Maier, C.,; Holzer, P.,; Mikus, G.,; Bosse, B.,; Smith, K.,; Buschmann-Kramm, C.,; Leyendecker, P., Meeting the challenges of opioid-induced constipation in chronic pain management - a novel approach. Pharmacology 2009, 83, 10–17.
81. Croset, M.,; Rajas, F.,; Zitoun, C.,; Hurot, J.M.,; Montano, S.,; Mithieux, G., Rat small intestine is an insulin-sensitive gluconeogenic organ. Diabetes 2001, 50, 740–746.
82. Mithieux, G.,; Bady, I.,; Gautier, A.,; Croset, M.,; Rajas, F.,; Zitoun, C., Induction of control genes in intestinal gluconeogenesis is sequential during fasting and maximal in diabetes. Am. J. Physiol. Endocrinol. Metab. 2004, 286, E370–E375.
83. Mithieux, G.,; Rajas, F.,; Gautier-Stein, A., A novel role for glucose 6-phosphatase in the small intestine in the control of glucose homeostasis. J. Biol. Chem. 2004, 279, 44231–44234.
84. Rajas, F.,; Bruni, N.,; Montano, S.,; Zitoun, C.,; Mithieux, G., The glucose-6 phosphatase gene is expressed in human and rat small intestine: regulation of expression in fasted and diabetic rats. Gastroenterology 1999, 117, 132–139.
85. Rajas, F.,; Croset, M.,; Zitoun, C.,; Montano, S.,; Mithieux, G., Induction of PEPCK gene expression in insulinopenia in rat small intestine. Diabetes 2000, 49, 1165–1168.
86. Mithieux, G., A novel function of intestinal gluconeogenesis: Central signaling in glucose and energy homeostasis. Nutrition 2009, 25, 881–884.
87. Duraffourd, C.,; De Vadder, F.,; Goncalves, D.,; Delaere, F.,; Penhoat, A.,; Brusset, B.,; Rajas, F.,; Chassard, D.,; Duchampt, A.,; Stefanutti, A.,; Gautier-Stein, A.,; Mithieux, G., Mu-opioid receptors and dietary protein stimulate a gut-brain neural circuitry limiting food intake. Cell 2012, 150, 377–388.
88. Mithieux, G.,; Misery, P.,; Magnan, C.,; Pillot, B.,; Gautier-Stein, A.,; Bernard, C.,; Rajas, F.,; Zitoun, C., Portal sensing of intestinal gluconeogenesis is a mechanistic link in the diminution of food intake induced by diet protein. Cell Metab. 2005, 2, 321–329.
89. Penhoat, A.,; Mutel, E.,; Amigo-Correig, M.,; Pillot, B.,; Stefanutti, A.,; Rajas, F.,; Mithieux, G., Protein-induced satiety is abolished in the absence of intestinal gluconeogenesis. Physiol. Behav. 2011, 105, 89–93.
90. Troy, S,; Soty, M.; Ribeiro, L.,; Laval, L.; Migrenne, S.,; Fioramonti, X.,; Pillot, B.,; Fauveau, V. Aubert, R.,; Viollet, B.,; Foretz, M.,; Leclerc, J.,; Duchampt, A.,; Zitoun, C.,; Thorens, B.,; Magnan, C.,; Mithieux, G.,; Andreelli, F., Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice. Cell Metab. 2008, 8, 201–211.
91. Glass, M.J.,; Billington, C.J.,; Levine, A.S., Opioids and food intake: distributed functional neural pathways? Neuropeptides 1999, 33, 360–368.
92. Shin, A.C.,; Pistell, P.J.,; Phifer, C.B.,; Berthoud, H.R., Reversible suppression of food reward behavior by chronic mu-opioid receptor antagonism in the nucleus accumbens. Neuroscience. 2010, 170, 580–588.
93. Reichelt, K.L,; Stensrud, M., Increase in urinary peptides prior to the diagnosis of schizophrenia. Schizophr. Res. 1998, 34, 211–3.
94. Todd, T.,; Reid, G.,; Butler-Kisber, L., Cycling for students with ASD: Self-regulation promotes sustained physical activity. Adapted Phy. Activity Q. 2010, 27, 226–241.
95. Cass, H.,; Gringras, P.,; March, J.,; McKendrick, I.,; O’Hare, A.E., Owe absence of urinary opioid peptides in children with autism. Arch. Dis. Child 2008, 93, 745–750.
96. Sokolov, O.,; Kost, N.,; Andreeva, O.,; Korneeva, E.,; Meshavkin, V.,; Tarakanova, Y.,; Dadayan, A,; Zolotare, Y.,; Grachev, S.,; Mikheeva, I.,; Varlamov, O.,; Zozulya, A., Autistic children display elevated urine levels of bovine casomorphin-7 immunoreactivity. Peptides 2014, 56, 68–71.
97. Trivedi, M.S.,; Shah, J.S.,; Al-Mughairy, S.,; Hodgson, N.W.,; Simms, B.,; Trooskens, G.A.,; Van Criekinge, W.,; Deth, R.C., Food-derived opioid peptides inhibit cysteine uptake with redox and epigenetic consequences. J. Nutr. Biochem. 2014, 25, 1011–1018.
98. Augustyns, K.,; Van der Veken, P.,; Senten, K.,; Haemers, A., The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases. Curr. Med. Chem. 2005, 12, 971–998.
99. De Meester, I.,; Durinx, C.,; Bal, G.,; Proost, P.,; Struyf, S.,; Goossens, F.,; Augustyns, K.,; Scharpé, S., Natural substrates of dipeptidyl peptidase IV. Adv. Exp. Med. Biol. 2000, 477, 67–87.
100. Vanhoof, G.,; Goossens, F.,; De Meester, I.,; Hendriks, D.,; Scharpe, S., Proline motifs in peptides and their biological processing. FASEB J. 1995, 9, 736–744.
101. Augustyns, K.,; Bal, G.,; Thonus, G.,; Belyaev, A.,; Zhang, X.M.,; Bollaert, W.,; Lambeir, A.M.,; Durinx, C.,; Goossens, F.,; Haemers, A., The unique properties of dipeptidyl-peptidase IV (DPP IV /CD26) and the therapeutic potential of DPP IV inhibitors. Curr. Med. Chem. 1999, 6, 311–327.
102. Mentlein, R., Dipeptidyl-peptidase IV, (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 1999, 85, 9–24.
103. Rahfeld, J.,; Schierhorn, M.,; Hartrodt, B.,; Neubert, K.,; Heins, J., Are diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) inhibitors or substrates of dipeptidyl peptidase IV? Biochim. Biophys. Acta. 1991, 1076, 314–316.
104. Bethune, M.T.,; Khosla, C., Oral enzyme therapy for celiac sprue. Methods Enzymol. 2012, 502, 241–271.
105. Hausch, F.,; Shan, L.,; Santiago, N.A.,; Gray, G.M.,; Khosla, C., Intestinal digestive resistance of immunodominant gliadin peptides. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 283, G996–G1003.
106. Detel, D.,; Persic, M.,; Varljen, J., Serum and intestinal dipeptidyl peptidase IV (DPP IV/CD26) activity in children with celiac disease. J. Pediatr. Gastroenterol. Nutr. 2007, 45, 65–70.
107. Ozuna, C.V.,; Iehisa, J.C.,; Gimenez, M.J.,; Alvarez, J.B.,; Sousa, C.,; Barro, F., Diversification of the celiac disease alpha-gliadin complex in wheat: a 33-mer peptide with six overlapping epitopes, evolved following polyploidization. Plant J. 2015, 82, 794–805.
108. Shan, L.,; Molberg, O.,; Parrot, I.,; Hausch, F.,; Filiz, F.,; Gray, G.M.,; Sollid, L.M.; Khosla, C. Structural basis for gluten intolerance in celiac sprue. Science 2002, 297, 2275–2279.
109. Vojdani, A., Identification of etiology of autism. 2005 US20050170333 A1.
110. Troncone, R.,; Jabri, B., Coeliac disease and gluten sensitivity. J. Intern. Med. 2011, 269, 582–590.
111. Strohle, A.,; Wolters, M.,; Hahn, A., Celiac disease–the chameleon among the food intolerances. Med. Monatsschr. Pharm. 2013, 36, 369–380.
112. Tovoli, F.,; Masi, C.,; Guidetti, E.,; Negrini, G.,; Paterini, P.,; Bolondi, L., Clinical and diagnostic aspects of gluten related disorders. World J. Clin. Cases 2015, 3, 275–284.
113. Urgesi, R.,; Cianci, R.,; Bizzotto, A.,; Costamagna, G.,; Riccioni, M.E., Evaluation of gastric and small bowel transit times in coeliac disease with the small bowel PillCam(R): A single centre study in a non gluten-free diet adult Italian population with coeliac disease. Eur. Rev. Med. Pharmacol. Sci. 2013, 17, 1167–1173.
114. Fukudome, S.,; Shimatsu, A.,; Suganuma, H.,; Yoshikawa, M., Effect of gluten exorphins A5 and B5 on the postprandial plasma insulin level in conscious rats. Life Sci. 1995, 57, 729–734.
115. Delvecchio, M.,; Faienza, M.F.,; Lonero, A.,; Rutigliano, V.,; Francavilla, R.,; Cavallo, L., Prolactin may be increased in newly diagnosed celiac children and adolescents and decreases after 6 months of gluten-free diet. Horm. Res. Paediatr. 2014, 81, 309–313.
116. Fanciulli, G.,; Dettori, A.,; Tomasi, P.A.,; Demontis, M.P.,; Gianorso, S.,; Anania, V.,; Delitala, G. Prolactin and growth hormone response to intracerebroventricular administration of the food opioid peptide gluten exorphin B5 in rats. Life Sci. 2002, 71, 2383–2390.
117. Takahashi, M.,; Fukunaga, H.,; Kaneto, H.,; Fukudome, S.,; Yoshikawa, M., Behavioral and pharmacological studies on gluten exorphin A5, a newly isolated bioactive food protein fragment, in mice. Jpn. J. Pharmacol. 2000, 84, 259–265.
118. Cade, R.J.,; Privette, R.M.,; Fregly, M.,; Rowland, N.,; Sun, Z.,; Zele, V.,; Wagemaker, H.,; Edelstein, C., Autism and schizophrenia: intestinal disorders. Nutr. Neurosci. 2000, 3, 57–72.
119. Reichelt, K.L.,; Ekrem, J.,; Scott, H., Gluten, milk proteins and autism: dietary intervention effects on behavior and peptide secretion. J. Appl. Nutr. 1990, 42, 1–11.
120. Kawashti, M.I.,; Amin, O.H.,; Rowely, N.G., Possible immunological disorders in autism. Concomittant autoimmunity and immune tolerance. Egypt J. Immunol. 2008, 13, 99–104.
121. Trajkovski, V.,; Petlichkovski, A.,; Efinska-Mladenovske, O.,; Trajkov, D.,; Arsov, T.,; Strzova, A., Higher plasma concentrations of food specific antibodies in persons with autistic disorder in comparison to their siblings. Focus on autism and other developmental disabilities. 2008, 23, 176–186.
122. Voidani, A.,; O’Brian, T.,; Green, J.A.,; McCandless, J.,; Woeller, K.N.,; Vojdani, A.A., Immune response to dietary proteins, Gliadin and Cerebellar peptides in children and autism. Nutritional Neurosci. 2004, 7, 151–161.
123. Bender, L., Childhood Schizophrenia. Psychiatr. Q., 1953, 27, 663–681.
124. Morley, J.E., Food peptides. A new class of hormones? JAMA. 1982, 247, 2379–2380.
125. Righard, L.,; Carlsson-Jonsson, A.,; Nyberg, B., Enhanced levels of immunoreactive β-casomorphin-8 in milk of breastfeeding women with mastitis. Peptides 2014, 51, 54–58.
126. Lindstrome, L.H.,; Nyberg, F.,; Terenius, L.,; Bauer, K.,; Besev, G.,; Gunne, L.M. CSF, and plasma β-casomorphin-like opioid peptides in postpartum psychosis. Am. J. Psichiatry 1984, 141, 1059–1066.
127. Peruzzo, B.,; Pastor, F.E.,; Blázquez, J.L.,; Schöbitz, K.,; Peláez, B.,; Amat, P.,; Rodríguez, E.M., A second look at the barriers of the medial basal hypothalamus. Exp. Brain. Res. 2000, 132, 10–26.
128. Kuich, T.E.,; Zimmerman, C., Could endorphins be implicated in sudden-infant-death syndrome? N. Eng. J. Med. 1981, 304, 973.
129. Hemmings, W.A.,; Williams, E.W., Quantitative and visualization studies of the transport of rat and bovine IgG and ferritin across the segments of the small intestine of the suckling rat. Proc R. Soc. Lond. B Biol. Sci. 1977, 197, 425–440.
130. Hemmings, W.A., The entry into the brain of large molecules derived from dietary protein. Proc. R. Soc. Lond. B Biol. Sci. 1978, 200, 175–192.
131. Hemmings, W.A.,; Williams, E.W., Transport of large breakdown products of dietary protein through the gut wall. Gut. 1978, 19, 715–723.
132. Williams, E.W.,; Hemmings, W.A., Intestinal uptake and transport of proteins in the adult rat. Proc. R. Soc. Lond. B Biol. Sci. 1978, 203, 177–189.
133. Greenberg, R.,; Groves, M.L.,; Peterson, R.F., Amino terminal sequence and location of phosphate groups of the major human casein. J. Dairy Sci. 1976, 59, 1016–1018.
134. Greenberg, R.,; Whalley, C.E.,; Jourdikian, F.,; Mendelson, I.S.,; Walter, R.,; Nikolics, K.,; Coy, D.H.,; Schally, A.V.,; Kastin, A.J., Peptides readily penetrate the blood-brain barrier: uptake of peptides by synaptosomes is passive. Pharmacol. Biochem. Behav. 1976, 5, 151–158.
135. Arck, P.,; Handjiski, B.,; Hagen, E.,; Pincus, M.,; Bruenahl, C.,; Bienenstock, J.,; Paus, R., Is there a ‘gut–brain–skin axis’? Exp. Dermatol. 2010, 19, 401–405.
136. Dohan, F.C., Genetic hypothesis of idiopathic schizophrenia: its exorphin connection. Schizophr. Bull. 1969, 14, 489–494.
137. Lister, J.,; Fletcher, P.J.,; Nobrega, J.N.,; Remington, G., Behavioral effects of food-derived opioid-like peptides in rodents: implications for schizophrenia? Pharmacol. Biochem. Behav. 2015, 134, 70–78.
138. Tveiten, D.,; Finvold, A.,; Andersson, M.,; Reichelt, K.L., Peptides and Exorphins in the Autism Spectrum. Open J. Psych. 2014, 4, 275–287.
139. Trivedi, M.S.,; Shah, J.S.,; Al-Mughairy, S.,; Hodgson, N.W.,; Simms, B.,; Trooskens, G.A.,; Van Criekinge, W.,; Dethal R.C., Food-derived opioid peptides inhibit cysteine uptake with redox and epigenetic consequences. J. Nutrit. Biochem. 2014, 25, 1011–1018.
140. Kaneko, K.,; Lazarus, M.,; Miyamoto, C.,; Oishi, Y.,; Nagata, N.,; Yang, S.,; Yoshikawa, M.,; Aritake, K.,; Furuyashiki, T.,; Narumiya, S.,; Urade, Y.,; Ohinata, K., Orally administered rubiscolin-6, a δ-opioid peptide derived from Rubisco, stimulates food intake via leptomeningeal lipocallin-type prostaglandin D synthase in mice. Mol. Nutr. Food Res. 2012, 56, 1315–1323.
141. Wadley, G.,; Martin, A., The origins of agriculture: A biological perspective and a new hypothesis. Australian Biologist. 1993, 6, 96–105.
142. Reid, L.D.,; Hubbell, C.L., An assessment of the addiction potential of the opioid associated with milk. J. Dairy Sci. 1994, 77, 672–675.
143. Teschemacher, H., Opioid receptor ligands derived from food proteins. Curr. Pharm. Des. 2003, 9, 1331–1344.
144. Pinto-Sánchez, M.I.; Bercík, P.; Verdu, E.F.; Bai, J.C. Extraintestinal manifestation of Celiac disease. Digestive Diseases 2015, 33, 147–154.